Download PDF
Am J Perinatol 2021; 38(S 01): e64-e70
DOI: 10.1055/s-0040-1705148
Original Article

The Effect of Antenatal Neuroprotective Magnesium Sulfate Treatment on Cerebral Oxygenation in Preterm Infants

Buse Ozer Bekmez 
1   Division of Neonatology, Zekai Tahir Burak Women's Health Education and Research Hospital, Altındağ, Ankara, Turkey
,
Yüksel Oğuz
2   Division of Perinatology, Zekai Tahir Burak Women's Health Education and Research Hospital, Altındağ, Ankara, Turkey
,
Hayriye Gözde Kanmaz Kutman
1   Division of Neonatology, Zekai Tahir Burak Women's Health Education and Research Hospital, Altındağ, Ankara, Turkey
,
Dilek Uygur
2   Division of Perinatology, Zekai Tahir Burak Women's Health Education and Research Hospital, Altındağ, Ankara, Turkey
,
Fuat Emre Canpolat 
1   Division of Neonatology, Zekai Tahir Burak Women's Health Education and Research Hospital, Altındağ, Ankara, Turkey
,
Serife Suna Oğuz
1   Division of Neonatology, Zekai Tahir Burak Women's Health Education and Research Hospital, Altındağ, Ankara, Turkey
,
Cüneyt Tayman
1   Division of Neonatology, Zekai Tahir Burak Women's Health Education and Research Hospital, Altındağ, Ankara, Turkey
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Objective Antenatal magnesium sulfate (MgSO4) treatment is associated with reduced risk of cerebral palsy in preterm infants. We aimed to investigate whether this treatment leads to any alterations on cerebral hemodynamics which could be detected by near-infrared spectroscopy (NIRS) readings in early postnatal life.

Study Design Infants with gestational ages (GAs) ≤ 32 weeks were divided into two groups regarding their exposure to antenatal neuroprotective MgSO4 treatment or not. NIRS monitoring was performed to all infants, and readings were recorded for 2 hours each day during the first 3 days of life. The primary aim was to compare regional cerebral oxygen saturation (rcSO2) and cerebral fractional tissue oxygen extraction (cFTOE) between the groups.

Results Sixty-six infants were exposed to antenatal MgSO4, while 64 of them did not. GA and birth weight were significantly lower in the treatment group (p < 0.01). No difference was observed in rcSO2 and cFTOE levels in the first, second, and the third days of life (p > 0.05). An insignificant reduction in severe intraventricular hemorrhage rates was observed (8 vs. 15%, p = 0.24).

Conclusion We could not demonstrate any effect on cerebral oxygenation of preterm infants in early postnatal life that could be attributed to antenatal neuroprotective MgSO4 treatment. Future studies are warranted to clarify the exact underlying mechanisms of neuroprotection.

Keywords

magnesium sulfate - neuroprotection - NIRS - infant


Publication History

Received: 20 April 2019

Accepted: 28 January 2020

Article published online:
06 March 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Doyle LW. ; Victorian Infant Collaborative Study Group. Outcome at 5 years of age of children 23 to 27 weeks' gestation: refining the prognosis. Pediatrics 2001; 108 (01) 134-141
    CrossrefPubMedGoogle Scholar
  • 2 Marlow N, Wolke D, Bracewell MA, Samara M. ; EPICure Study Group. Neurologic and developmental disability at six years of age after extremely preterm birth. N Engl J Med 2005; 352 (01) 9-19
    CrossrefPubMedGoogle Scholar
  • 3 Doyle LW, Crowther CA, Middleton P, Marret S, Rouse D. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev 2009; (01) CD004661
    PubMedGoogle Scholar
  • 4 Kuban KCK, Leviton A, Pagano M, Fenton T, Strassfeld R, Wolff M. Maternal toxemia is associated with reduced incidence of germinal matrix hemorrhage in premature babies. J Child Neurol 1992; 7 (01) 70-76
    CrossrefPubMedGoogle Scholar
  • 5 Rouse DJ, Hirtz DG, Thom E. et al; Eunice Kennedy Shriver NICHD Maternal-Fetal Medicine Units Network. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med 2008; 359 (09) 895-905
    CrossrefPubMedGoogle Scholar
  • 6 Marret S, Marpeau L, Zupan-Simunek V. et al; PREMAG trial group. Magnesium sulphate given before very-preterm birth to protect infant brain: the randomised controlled PREMAG trial. BJOG 2007; 114 (03) 310-318
    CrossrefPubMedGoogle Scholar
  • 7 Crowther CA, Hiller JE, Doyle LW, Haslam RR. ; Australasian Collaborative Trial of Magnesium Sulphate (ACTOMg SO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA 2003; 290 (20) 2669-2676
    CrossrefPubMedGoogle Scholar
  • 8 Costantine MM, Weiner SJ. ; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Effects of antenatal exposure to magnesium sulfate on neuroprotection and mortality in preterm infants: a meta-analysis. Obstet Gynecol 2009; 114 (2 Pt 1): 354-364
    CrossrefPubMedGoogle Scholar
  • 9 Conde-Agudelo A, Romero R. Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis. Am J Obstet Gynecol 2009; 200 (06) 595-609
    CrossrefPubMedGoogle Scholar
  • 10 Doyle LW, Crowther CA, Middleton P, Marret S. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev 2007; (03) CD004661
    PubMedGoogle Scholar
  • 11 Crowther CA, Middleton PF, Voysey M. et al; AMICABLE Group. Assessing the neuroprotective benefits for babies of antenatal magnesium sulphate: an individual participant data meta-analysis. PLoS Med 2017; 14 (10) e1002398
    CrossrefPubMedGoogle Scholar
  • 12 Zeng X, Xue Y, Tian Q, Sun R, An R. Effects and safety of magnesium sulfate on neuroprotection: a meta-analysis based on PRISMA guidelines. Medicine (Baltimore) 2016; 95 (01) e2451
    CrossrefPubMedGoogle Scholar
  • 13 Hirtz DG, Weiner SJ, Bulas D. et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Antenatal magnesium and cerebral palsy in preterm infants. J Pediatr 2015; 167 (04) 834-839.e3
    CrossrefPubMedGoogle Scholar
  • 14 Gano D, Ho ML, Partridge JC. et al. Antenatal exposure to magnesium sulfate is associated with reduced cerebellar hemorrhage in preterm newborns. J Pediatr 2016; 178: 68-74
    CrossrefPubMedGoogle Scholar
  • 15 Magee L, Sawchuck D, Synnes A, von Dadelszen P. ; Magnesium Sulphate for Fetal Neuroprotection Consensus Committee; Maternal Fetal Medicine Committee. SOGC Clinical Practice Guideline. Magnesium sulphate for fetal neuroprotection. J Obstet Gynaecol Can 2011; 33 (05) 516-529
    CrossrefPubMedGoogle Scholar
  • 16 da Costa CS, Greisen G, Austin T. Is near-infrared spectroscopy clinically useful in the preterm infant?. Arch Dis Child Fetal Neonatal Ed 2015; 100 (06) F558-F561
    CrossrefPubMedGoogle Scholar
  • 17 Pellicer A, Greisen G, Benders M. et al. The SafeBoosC phase II randomised clinical trial: a treatment guideline for targeted near-infrared-derived cerebral tissue oxygenation versus standard treatment in extremely preterm infants. Neonatology 2013; 104 (03) 171-178
    CrossrefPubMedGoogle Scholar
  • 18 Hyttel-Sørensen S, Austin T, van Bel F. et al. Clinical use of cerebral oximetry in extremely preterm infants is feasible. Dan Med J 2013; 60 (01) A4533
    PubMedGoogle Scholar
  • 19 Plomgaard AM, van Oeveren W, Petersen TH. et al. The SafeBoosC II randomized trial: treatment guided by near-infrared spectroscopy reduces cerebral hypoxia without changing early biomarkers of brain injury. Pediatr Res 2016; 79 (04) 528-535
    CrossrefPubMedGoogle Scholar
  • 20 Hyttel-Sorensen S, Greisen G, Als-Nielsen B, Gluud C. Cerebral near-infrared spectroscopy monitoring for prevention of brain injury in very preterm infants. Cochrane Database Syst Rev 2017; 9 (09) CD011506
    PubMedGoogle Scholar
  • 21 Stark MJ, Hodyl NA, Andersen CC. Effects of antenatal magnesium sulfate treatment for neonatal neuro-protection on cerebral oxygen kinetics. Pediatr Res 2015; 78 (03) 310-314
    CrossrefPubMedGoogle Scholar
  • 22 Verhagen EA, Kooi EM, van den Berg PP, Bos AF. Maternal antihypertensive drugs may influence cerebral oxygen extraction in preterm infants during the first days after birth. J Matern Fetal Neonatal Med 2013; 26 (09) 871-876
    CrossrefPubMedGoogle Scholar
  • 23 Richter AE, Schat TE, Van Braeckel KN, Scherjon SA, Bos AF, Kooi EM. The effect of maternal antihypertensive drugs on the cerebral, renal and splanchnic tissue oxygen extraction of preterm neonates. Neonatology 2016; 110 (03) 163-171
    CrossrefPubMedGoogle Scholar
  • 24 Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr 1978; 92 (04) 529-534
    CrossrefPubMedGoogle Scholar
  • 25 Marret S, Doyle LW, Crowther CA, Middleton P. Antenatal magnesium sulphate neuroprotection in the preterm infant. Semin Fetal Neonatal Med 2007; 12 (04) 311-317
    CrossrefPubMedGoogle Scholar
  • 26 Chollat C, Sentilhes L, Marret S. Fetal neuroprotection by magnesium sulfate: from translational research to clinical application. Front Neurol 2018; 9: 247
    CrossrefPubMedGoogle Scholar
  • 27 Imamoglu EY, Gursoy T, Karatekin G, Ovali F. Effects of antenatal magnesium sulfate treatment on cerebral blood flow velocities in preterm neonates. J Perinatol 2014; 34 (03) 192-196
    CrossrefPubMedGoogle Scholar
  • 28 Narasimhulu D, Brown A, Egbert NM. et al. Maternal magnesium therapy, neonatal serum magnesium concentration and immediate neonatal outcomes. J Perinatol 2017; 37 (12) 1297-1303
    CrossrefPubMedGoogle Scholar
  • 29 Lecuyer M, Rubio M, Chollat C. et al. Experimental and clinical evidence of differential effects of magnesium sulfate on neuroprotection and angiogenesis in the fetal brain. Pharmacol Res Perspect 2017;5(04):
    PubMedGoogle Scholar
  • 30 Macdonald RL, Curry DJ, Aihara Y, Zhang ZD, Jahromi BS, Yassari R. Magnesium and experimental vasospasm. J Neurosurg 2004; 100 (01) 106-110
    Google Scholar
  • 31 Altura BT, Altura BM. Withdrawal of magnesium causes vasospasm while elevated magnesium produces relaxation of tone in cerebral arteries. Neurosci Lett 1980; 20 (03) 323-327
    CrossrefPubMedGoogle Scholar
  • 32 Seelig JM, Wei EP, Kontos HA, Choi SC, Becker DP. Effect of changes in magnesium ion concentration on cat cerebral arterioles. Am J Physiol 1983; 245 (01) H22-H26
    PubMedGoogle Scholar
  • 33 Euser AG, Cipolla MJ. Resistance artery vasodilation to magnesium sulfate during pregnancy and the postpartum state. Am J Physiol Heart Circ Physiol 2005; 288 (04) H1521-H1525
    CrossrefPubMedGoogle Scholar
  • 34 Escalona-Vargas DI, Thagard AS, McGrail K. et al. Observations of fetal brain activity via non-invasive magnetoencephalography following administration of magnesium sulfate for neuroprotection in preterm labor. Prenat Diagn 2016; 36 (10) 982-984
    CrossrefPubMedGoogle Scholar
  • 35 Galinsky R, Draghi V, Wassink G. et al. Magnesium sulfate reduces EEG activity but is not neuroprotective after asphyxia in preterm fetal sheep. J Cereb Blood Flow Metab 2017; 37 (04) 1362-1373
    CrossrefPubMedGoogle Scholar
  • 36 Greisen G. Cerebral autoregulation in preterm infants. How to measure it--and why care?. J Pediatr 2014; 165 (05) 885-886
    CrossrefPubMedGoogle Scholar
  • 37 Hunter CL, Oei JL, Lui K, Schindler T. Cerebral oxygenation as measured by near-infrared spectroscopy in neonatal intensive care: correlation with arterial oxygenation. Acta Paediatr 2017; 106 (07) 1073-1078
    CrossrefPubMedGoogle Scholar
  • 38 Alderliesten T, Dix L, Baerts W. et al. Reference values of regional cerebral oxygen saturation during the first 3 days of life in preterm neonates. Pediatr Res 2016; 79 (1-1): 55-64
    CrossrefPubMedGoogle Scholar
  • 39 Lemmers PM, Toet M, van Schelven LJ, van Bel F. Cerebral oxygenation and cerebral oxygen extraction in the preterm infant: the impact of respiratory distress syndrome. Exp Brain Res 2006; 173 (03) 458-467
    CrossrefPubMedGoogle Scholar
  • 40 Moran M, Miletin J, Pichova K, Dempsey EM. Cerebral tissue oxygenation index and superior vena cava blood flow in the very low birth weight infant. Acta Paediatr 2009; 98 (01) 43-46
    CrossrefPubMedGoogle Scholar
  • 41 Naulaers G, Morren G, Van Huffel S, Casaer P, Devlieger H. Cerebral tissue oxygenation index in very premature infants. Arch Dis Child Fetal Neonatal Ed 2002; 87 (03) F189-F192
    CrossrefPubMedGoogle Scholar
  • 42 Pichler G, Binder C, Avian A, Beckenbach E, Schmölzer GM, Urlesberger B. Reference ranges for regional cerebral tissue oxygen saturation and fractional oxygen extraction in neonates during immediate transition after birth. J Pediatr 2013; 163 (06) 1558-1563
    CrossrefPubMedGoogle Scholar